Department of General and Visceral Surgery, University Hospital of Muenster, Muenster, Germany.
Ann Surg Oncol. 2009 Nov;16(11):3183-9. doi: 10.1245/s10434-009-0623-1. Epub 2009 Jul 28.
Pancreatic ductal adenocarcinoma (PDAC) is known for its very poor overall prognosis, making tools for early diagnosis and new therapeutic modalities urgently needed. MicroRNAs (miRNAs), endogenous noncoding RNA molecules of approximately 22 nt, have gained attention as an epigenetic component involved in the development of many cancers, including PDAC. miRNA expression profiles of varying pancreatic tissues have identified a number of differentially expressed miRNAs and seem to be able to differentiate between three tissues of clinical importance: normal pancreas, chronic pancreatitis, and PDAC. This article gathers our current knowledge of differentially expressed miRNAs in pancreatic tissues with relevance to PDAC and presents potential diagnostic and therapeutic opportunities.
胰腺导管腺癌 (PDAC) 的总体预后极差，因此迫切需要用于早期诊断和新治疗方式的工具。微小 RNA（miRNA）是大约 22 个核苷酸的内源性非编码 RNA 分子，作为涉及多种癌症（包括 PDAC）发展的表观遗传成分而受到关注。不同胰腺组织的 miRNA 表达谱已经确定了许多差异表达的 miRNA，并且似乎能够区分三种具有临床重要性的组织：正常胰腺、慢性胰腺炎和 PDAC。本文汇集了我们目前对与 PDAC 相关的胰腺组织中差异表达 miRNA 的了解，并提出了潜在的诊断和治疗机会。
